Key result
Long-term outpatient infusions of dobutamine and oral sympathomimetic amines for heart failure were historically associated with excess mortality.
Answers are grounded in this paper and cite their sources.
This editorial provides a historical perspective on the shift away from long-term inotropic therapy in heart failure due to associated excess mortality.
Looking back reveals how the direction of therapy for heart failure has changed since the inception of the first large clinical trial of vesnarinone, an inotropic agent, in April 1990. At that time, many investigators remained interested in the concept of heart failure as a defect that could be remedied by drugs that enhanced cardiac contractility.1 Intravenous dopamine and dobutamine were widely used to increase cardiac output with less chronotropy and fewer arrhythmias than the more potent adrenergic agonists isoproterenol, epinephrine, and norepinephrine. Even though excess mortality was found with long-term outpatient infusions of dobutamine and the oral sympathomimetic amines . . .
No takes yet. Share an insight, caveat, or question.
Lynne W. Stevenson (1998) conducted an editorial in Heart failure. Inotropic therapy was evaluated. Long-term outpatient infusions of dobutamine and oral sympathomimetic amines for heart failure were historically associated with excess mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: